docetaxel anhydrous has been researched along with Cancer of Jaw in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Igawa, Y; Ishikawa, A; Kume, H; Miyazaki, H; Nishimatsu, H; Suzuki, M | 1 |
1 other study(ies) available for docetaxel anhydrous and Cancer of Jaw
| Article | Year |
|---|---|
Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Incidence; Japan; Jaw Neoplasms; Leukopenia; Male; Middle Aged; Osteonecrosis; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Zoledronic Acid | 2012 |